|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Cephalon
gptkb:Actavis'_generics_business
gptkb:Actavis_Generics
gptkb:Ratiopharm
Allergan's generics business
|
|
gptkbp:ceo
|
gptkb:Kåre_Schultz
|
|
gptkbp:employees
|
over 40,000
|
|
gptkbp:founded
|
1901
|
|
gptkbp:global_presence
|
over 60 countries
|
|
gptkbp:headcount
|
over 40,000
|
|
gptkbp:headquarters
|
Petah Tikva, Israel
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Teva (2000)
|
|
gptkbp:industry
|
Pharmaceuticals
|
|
gptkbp:invention
|
Over 1,000
|
|
gptkbp:market
|
Global
|
|
gptkbp:market_share
|
Top 10 in global generics
Top 5 in specialty pharmaceuticals
|
|
gptkbp:partnership
|
gptkb:Mylan
gptkb:Boehringer_Ingelheim
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
|
|
gptkbp:products
|
Generic drugs
Specialty medicines
|
|
gptkbp:research_and_development
|
$1.3 billion (2020)
|
|
gptkbp:revenue
|
$16.7 billion (2020)
|
|
gptkbp:stock_exchange
|
gptkb:NYSE
|
|
gptkbp:stock_symbol
|
gptkb:TEVA
|
|
gptkbp:subsidiary
|
gptkb:Teva_Pharmaceuticals_USA
gptkb:Teva_Pharmaceuticals_Europe_B._V.
gptkb:Teva_Canada_Limited
gptkb:Teva_UK_Limited
|
|
gptkbp:sustainability_initiatives
|
gptkb:administration
Social responsibility
Environmental responsibility
|
|
gptkbp:bfsParent
|
gptkb:Deckers_Outdoor_Corporation
|
|
gptkbp:bfsLayer
|
5
|